Home System concept COUR Pharmaceuticals Announces First Human Assay in Proof of Concept Trial of CNP-201 to Treat Peanut Allergy

COUR Pharmaceuticals Announces First Human Assay in Proof of Concept Trial of CNP-201 to Treat Peanut Allergy

0


CNP-201 is a nanoparticle containing peanut protein which aims to eliminate allergic reactions

Posted: October 19, 2021 at 9:00 a.m. EDT|Update: 2 hours ago

CHICAGO, October 19, 2021 / PRNewswire / – COUR Pharmaceuticals, a biotechnology company developing novel immuno-modifying nanoparticles to treat immune disorders (CNP), today announced that the first patient received a dose in the first proof of concept in the man (Phase 1b/ 2a) of its lead candidate, CNP-201, for the treatment of peanut allergy. The trial will evaluate the safety and efficacy of CNP-201 in people aged 16 to 55 years with peanut allergies and is being led by Kari nadeau, MD, Ph.D., director of the Sean N. Parker Center for Allergy and Asthma Research at Stanford University.

(PRNewsfoto / COUR Pharmaceuticals)

“Administering CNP-201 to our first patients is an important milestone for COUR Pharmaceuticals as it brings us one step closer to finding a cure for the most common food allergy in children under 18 years of age. and the second most common food allergy in adults. ,” noted Jean J. Puisis, co-founder, president and CEO of COUR. “This study will produce important clinical data to guide the future of COUR and continues to demonstrate our commitment to our patients.”

A recent study in the Journal of Allergy and Clinical Immunology found that up to 4.6 million American adults are allergic to peanuts. The immune system of people with peanut allergies can trigger an abnormal immune response to even small amounts of peanuts and trigger a severe reaction within minutes, leading to life-threatening anaphylaxis.

“The medical research of Arizona, the research division of Allergy, Asthma & Immunology Associates, is delighted to have recruited and treated the first patient in the CNP-201-5.001 peanut allergy clinical study. This study will provide new treatment options for our patients with peanut allergy, ”said Dr. Michael manning, Principal Investigator and CEO of Medical Research of Arizona. “Peanut allergy is a Th2 cell-mediated immune response against peanut protein epitopes. The potential of CNP-201 to inhibit the peanut-specific Th2 cell response through immune reprogramming could potentially abrogate peanut allergy and thus reduce the burdens associated with a lifelong peanut-free diet and the severe risk of death associated with a severe allergic reaction to peanuts. We look forward to our continued contributions to this groundbreaking study, which could eventually replace OIT therapy.

CNP-201 is a biodegradable nanoparticle encapsulating a peanut protein extract purified and administered by intravenous infusion. Nanoparticles containing peanut allergens are consumed by immune presenting cells. When particles and allergens are presented within the immune processing cell, they cause the cellular functions of the immune system to be reprogrammed, reducing and possibly eliminating the potential risk of serious allergic reactions.

COUR’s revolutionary nanoparticle immune modification platform, which preserves all immune functionality, is potentially applicable in the treatment of any autoimmune or allergic disease.

Active and candidate clinical sites:

  • Associated with Santa Clara Valley Allergies and Asthma- Alan goldsobel (http://www.allergycare.com)
  • Allergy and Asthma, San Diego- Alexandre griener, MD (https://allergyandasthma.com)
  • Dallas allergy and asthma Gary Gross, MD (https://www.daac-prc.com)
  • Medical research Arizona, Scottsdale- Michael manning, MD (https://www.medicalresearchaz.com)
  • Peninsula Research Associates, Los Angeles-Lawrence Sher, MD (http://peninsularesearch.com)
  • Portland Allergy and Asthma Clinic – Stephen B. Fritz, MD (https://www.portland-allergy.com)
  • Seattle allergy and asthma- Dan Petroni, MD (https://seattleallergy.org/)
  • Stanford UniversitySharon chinthrajah, MD
  • Virginia Mason Medical Center – David Jeong, MD
  • Western Sky Medical Research, El Paso- Todd Funkhauser, MD (https://www.westernskymedicalresearch.com)

About COUR Pharmaceuticals

COUR Pharmaceuticals develops world-leading therapies designed to reprogram the immune system to achieve antigen-specific tolerance for immune-mediated diseases. COUR’s immunity-modifying nanoparticle platform treats the root cause of immune diseases, unlike traditional approaches, which only minimize symptoms by using toxic immune suppression. COUR’s flagship celiac disease product, in partnership with Takeda Pharmaceutical Company, is the first demonstration of the induction of antigen-specific immune tolerance in any autoimmune disease. Data from clinical and preclinical settings demonstrate the opportunity for the COUR nanoparticle platform to treat a wide range of immune and inflammatory conditions. The underlying technology was acquired from Northwestern University and is based on more than 30 years of research from the laboratory of Stephen D. Miller, Ph.D., Judy E. Guggenheim Research Professor in Microbiology-Immunology.

Media contact:
Julie ferguson
[email protected]
(312) 385-0098

View original content to download multimedia:

SOURCE COUR Pharmaceutical

The above press release has been provided courtesy of PRNewswire. The views, opinions and statements contained in the press release are not endorsed by Gray Media Group and do not necessarily state or reflect those of Gray Media Group, Inc.